PHA — Pharmacy
IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports S. 882 Patients Before Middlemen Act IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - "The Ensuring Community Access to Pharmacists Services (ECAPS) Act IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) CMS Plan Year 2027 Medicare Drug Price Negotiation Program list of negotiated drug prices and process for negotiations. IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals IPC is opposed to the HRSA 340B proposed rebate model IPC supports the Continuing Appropriations Act 2026 (Medicare Part D PBM Reform provisions). IPC supports the Break Up Big Medicine Act S. 3822 IPC supports Protecting Pharmacies in Medicaid Act S. 927
Lobbyists: mr MARK EUGENE KINNEY; JOHN A. COVELLO
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; SENATE; White House Office